Fred Hutch Cancer Center | Strategic Alliance Partners

Monjuvi added to Rituxan and Revlimid extended progression-free survival from 14 to 22 months in follicular lymphoma, according to Dr. Christina Poh.

The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.

A patient on the Monjuvi trial saw lymph nodes shrink 85%, with stable results a year later, supporting the FDA’s recent approval for follicular lymphoma.

New treatment combinations are transforming genitourinary cancer care, improving survival and quality of life while personalizing patient outcomes.

The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer and neuroendocrine carcinomas.

Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.

Patients with favorable-risk prostate cancer “should be aware that they don't need treatment right away,” one expert said.

When it comes to bladder cancer, it’s important to note the differences between muscle-invasive and non-muscle-invasive bladder cancer, as it can affect the staging of the cancer.

It’s key for patients with MPN-related fatigue to communicate changes they feel, especially as they “know their bodies very well,” a nurse told CURE®.